| 발표일자: |
2013년 04월 20일 (토) |
| 발표시간: |
15:48~15:56 |
| 발표번호: |
망막F-037 |
| 발표장소: |
B방 |
|
|
| Stanniocalcin-1 protects retinal ganglion cells by inhibiting apoptosis and oxidative damage |
| 성균관대학교 의과대학 삼성서울병원 안과(1), 삼성생명과학연구소(2), 서울대학교 의과대학 안과학교실(3), 서울대학교병원 의생명연구원(4) |
| 김상진(1,2), 윤지현(2), 김주아(2), 김태은(2), 이현주(3,4), 고정화(3,4), 박기호 (3,4), 오주연(3,4) |
| 목적 : Optic neuropathy including glaucoma is one of the leading causes of irreversible vision loss, and there are currently no effective therapies. The hallmark of pathophysiology of optic neuropathy is oxidative stress and apoptotic death of retinal ganglion cells (RGCs), a population of neurons in the central nervous system with their soma in the inner retina and axons in the optic nerve. We investigated that an anti-apoptotic protein stanniocalcin-1 (STC-1) can prevent loss of RGCs in vitro and in vivo.방법 : We investigated the effects of STC-1 on the apoptosis of RGCs and reactive oxygen species (ROS) production in the retina of rats with intraorbital optic nerve transection (ONT). In addition, we evaluated the STC-1 effect in cultures of RGCs with cobalt chloride (CoCl2) injury. 결과 : We found that intravitreal injection of STC-1 increased the number of RGCs in the retina at days 7 and 14 after ONT, and decreased the apoptosis and oxidative damage. In cultures, treatment with STC-1 dose-dependently increased the cell viability, and decreased the apoptosis and levels of reactive oxygen species in RGC-5 cells that were exposed to CoCl2. The expression of HIF-1α that was up-regulated by injury was significantly suppressed in the retina and RGC-5 cells by STC-1 treatment. 결론 : The results suggested that intravitreal injection of STC-1 might be a useful therapy for optic nerve diseases in which RGCs undergo apoptosis through oxidative stress. |
| |